SELLAS LIFE SCIENCES GROUP I

Sellas Life Sciences’ 17% rally sparks M&A buzz as new executive incentives tie to Phase 3 AML trial, hinting at a potential takeover surge.

Sellas Life Sciences (SLS) surges 17% after executive contract overhaul, sparking speculation on a possible takeover and driving a 66k‑contract options spike.

How SLS’s borrowing rate hike, shareholder meeting transparency and mining ticker overlap shape investor sentiment and strategic outlook.